npj Parkinson's Disease (Nov 2024)
Accelerating Parkinson’s Disease drug development with federated learning approaches
- Amit Khanna,
- Jamie Adams,
- Chrystalina Antoniades,
- Bastiaan R. Bloem,
- Camille Carroll,
- Jesse Cedarbaum,
- Joshua Cosman,
- David T. Dexter,
- Marissa F. Dockendorf,
- Jeremy Edgerton,
- Laura Gaetano,
- Erkuden Goikoetxea,
- Derek Hill,
- Fay Horak,
- Elena S. Izmailova,
- Tairmae Kangarloo,
- Dina Katabi,
- Catherine Kopil,
- Michael Lindemann,
- Jennifer Mammen,
- Kenneth Marek,
- Kevin McFarthing,
- Anat Mirelman,
- Martijn Muller,
- Gennaro Pagano,
- M. Judith Peterschmitt,
- Jie Ren,
- Lynn Rochester,
- Sakshi Sardar,
- Andrew Siderowf,
- Tanya Simuni,
- Diane Stephenson,
- Christine Swanson-Fischer,
- John A. Wagner,
- Graham B. Jones
Affiliations
- Amit Khanna
- Neuroscience Development, Novartis AG
- Jamie Adams
- Department of Neurology and Center for Health and Technology, University of Rochester
- Chrystalina Antoniades
- NeuroMetrology Lab, University of Oxford
- Bastiaan R. Bloem
- Radboud University Medical Centre
- Camille Carroll
- Translational and Clinical Research Institute, Newcastle University
- Jesse Cedarbaum
- Department of Neurology, Yale School of Medicine
- Joshua Cosman
- AbbVie Pharmaceuticals
- David T. Dexter
- Parkinson’s UK, 50 Broadway
- Marissa F. Dockendorf
- Merck & Co., Inc.
- Jeremy Edgerton
- Biogen Inc
- Laura Gaetano
- Neuroscience Development, Novartis AG
- Erkuden Goikoetxea
- UCB Pharmaceuticals
- Derek Hill
- Panoramic Digital Health
- Fay Horak
- Oregon Health and Science University
- Elena S. Izmailova
- Koneksa Health, One World Trade Center
- Tairmae Kangarloo
- Takeda Pharmaceuticals
- Dina Katabi
- Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology
- Catherine Kopil
- The Michael J. Fox Foundation for Parkinson’s Research
- Michael Lindemann
- F. Hoffmann-La Roche Ltd
- Jennifer Mammen
- University of Massachusetts, Dartmouth, College of Nursing and Health Sciences
- Kenneth Marek
- Institute for Neurodegenerative Disorders
- Kevin McFarthing
- Parkinson’s research advocate
- Anat Mirelman
- Faculty of Medicine and Sagol School of Neuroscience, Tel Aviv University and Tel Aviv Medical Center
- Martijn Muller
- Critical Path Institute for Parkinson’s Disease Consortium, Critical Path Institute, 1840 E River Rd, Suite 100
- Gennaro Pagano
- F. Hoffmann-La Roche
- M. Judith Peterschmitt
- Research and Development, Sanofi
- Jie Ren
- Merck & Co., Inc.
- Lynn Rochester
- Translational and Clinical Research Institute, Newcastle University
- Sakshi Sardar
- Critical Path Institute for Parkinson’s Disease Consortium, Critical Path Institute, 1840 E River Rd, Suite 100
- Andrew Siderowf
- University of Pennsylvania Perelman School of Medicine
- Tanya Simuni
- Feinberg School of Medicine, Northwestern University
- Diane Stephenson
- Critical Path Institute for Parkinson’s Disease Consortium, Critical Path Institute, 1840 E River Rd, Suite 100
- Christine Swanson-Fischer
- National Institute of Neurological Disorders and Stroke, National Institutes of Health
- John A. Wagner
- Koneksa Health, One World Trade Center
- Graham B. Jones
- Data, Design and Clinical Innovation, Novartis Pharmaceuticals
- DOI
- https://doi.org/10.1038/s41531-024-00837-5
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 9
Abstract
Abstract Parkinson’s Disease is a progressive neurodegenerative disorder afflicting almost 12 million people. Increased understanding of its complex and heterogenous disease pathology, etiology and symptom manifestations has resulted in the need to design, capture and interrogate substantial clinical datasets. Herein we advocate how advances in the deployment of artificial intelligence models for Federated Data Analysis and Federated Learning can help spearhead coordinated and sustainable approaches to address this grand challenge.
